

Smart Stock

Your dependable partner in creating wealth since 1989

20 Feb 2020

Hester Biosciences Ltd.

This report has been solely prepared with an intention to educate investors about the parameters / events / ratios to be considered before taking action in any stock. This report should not be construed as a call to Buy / Sell or any kind of action. Kindly perform due research and study and even consultation with your advisor.

Smart Stock

Price related information

Company Hester Biosciences Ltd.

Current Price (Rs) 1520

Perceived Risk Medium

Holding Period (months)

Till the story remains good

Recommended Portfolio weightage 2%

Market Capitalisation (Rs crores) 1318

Stock related information

NSE Symbol HESTERBIO

BSE Ticker 524669

Face Value (Rs) 10

Book Value (Rs) 223.89

Sector Pharmaceuticals

BSE Group "B"

Liquidity Average

BSE Index constituent S&P BSE Small Cap

- ✓ Hester Biosciences Limited is a WHO-GMP & GLP certified company, manufacturing animal vaccines, health products and diagnostic kits, located near Ahmedabad, Gujarat.
- ✓ It is the country's second largest poultry vaccine manufacturer.
- ✓ The Company provides medicinal and health product needs of poultry, sheep, goats, cattle
 and pigs.
- ✓ Hester has four business divisions; poultry vaccine, poultry health products, large animal vaccines and large animal health products.
- ✓ Product portfolio includes vaccines (about 50% share to Sales), medicines, feed supplements and disinfectants.
- ✓ Hester has set up a second plant in Kathmandu, Nepal.
- ✓ The company exports products to 17 countries with major contribution coming from Africa.

(Continued on page 5)

Financial Highlights (standalone)							
	03/'16	03/'17	03/'18	03/'19	12/'18*	12/'19*	
Total Income	100.89	123.22	135.25	171.19	41.56	43.39	
Other Income	1.19	0.73	1.88	3.10	0.56	1.46	
Interest	-3.69	-3.21	-2.32	-3.54	-0.94	-1.41	
Depreciation	-5.73	-5.51	-5.45	-7.57	-1.52	-2.45	
Tax	-5.63	-8.10	-13.15	-15.90	-4.62	-2.88	
Net Profit	19.22	24.84	30.56	43.85	11.86	7.73	
Equity	8.51	8.51	8.51	8.51	8.51	8.51	
EPS	22.59	29.19	35.91	51.53	13.94	9.08	
CEPS	29.32	35.66	42.31	60.42	15.72	11.96	
OPM%	33.96	31.20	36.35	39.32	43.3	30.1	
NPM%	19.05	20.16	22.59	25.62	28.54	17.81	
Dividend%	41%	53%	100%	110%			
* - 3 months	All EPS an	d CEPS calcu	lated on curre	nt Face Value	Rs	in Crores	

Smart VERC: 28, 9-B, Saket, Bhopal (India)

Year-wise Best past recommendations in our various products

Stock	Advice Date	Advise Price	Current Price	% change
Lupin Ltd.	12-01-1997	2	709	35350%
Shree Cement	01-05-1998	21	24552	116814%
Havells India Ltd.	03-01-1999	1.13	619	54679%
Whirlpool Of India Ltd.	29-12-2000	23	2253	9696%
Thermax Ltd.	10-05-2001	3	986	32767%
Kansai Nerolac Paints	04-05-2002	4	500	12400%
Schaeffler India Ltd.	21-02-2003	56	4593	8102%
Honeywell Automation	23-07-2004	344	34896	10044%
Axis Bank Ltd.	25-11-2005	48	741	1444%
Honeywell Automation	23-06-2006	1193	34896	2825%
VenkyS (India) Ltd.	05-11-2007	77	1412	1734%
Elgi Equipments	14-03-2008	24	226	842%
Gabriel India Ltd.	27-03-2009	3	103	3333%
Sudarshan Chemical Ind.	26-02-2010	37	461	1146%
Avanti Feeds Ltd.	18-11-2011	22	520	2264%
Page Industries Ltd.	25-02-2011	1517	22930	1412%
Bajaj Finance Ltd.	27-05-2011	62	4877	7766%
KRBL Ltd.	06-04-2012	18	305	1594%
Bajaj Finance Ltd.	17-10-2012	122	4877	3898%
Caplin Point Laboratories	03-06-2013	14	352	2414%
Control Print Ltd.	26-02-2014	40	277	593%
Bajaj Finance Ltd.	21-01-2015	389	4877	1154%
Deepak Nitrite Ltd.	16-03-2016	63	483	667%
Aarti Industries	21-06-2017	475	997	110%
Ion Exchange	19-09-2018	408	903	121%
GMM Pfaudler	06-11-2018	1080	3350	210%
GMM Pfaudler	13-11-2019	1490	3350	125%
Canfin Homes	08-01-2020	388	510	31%

Smart VERC: 28, 9-B, Saket, Bhopal (India)



(Continued from page 3)

- ✓ There is hardly any debt in its books.
- During last three years Sales has jumped by 71% without any dilution in Equity. Debt has declined considerably. Thus it is able to generate enough earnings so as to finance its expansion plans and also repay debt obligations.
- Recently it has signed up an agreement with NOVAPHARMA for Technical Collaboration & Licensing to provide technology and support to set up an animal vaccines manufacturing facility in Egypt.
- ✓ As for the future,
 - It plans to develop new generation vaccines,
 - increase the product range,
 - Creation of an International marketing & distribution network with a focus on Africa, and
 - looking for a distribution / manufacturing joint ventures.
- ✓ With Reserves at 21 times Equity, stock is ripe for another bonus, last bonus was declared in Dec 2012 in 1:2 ratio.
- ✓ Dividend payouts are pretty good.
- ✓ Even stock split is a possibility.

(Continued on page 7)

Download App - Smart VERC



https://bit.ly/2EUU1aF



https://apple.co/2EXjaBA

More Value Added Features on our Website https://www.smartverc.com/

Investment /Retirement Calculator: https://www.smartverc.com/investment-calculator

Know your risk return profile: https://www.smartverc.com/riskprofile

For online subscription visit: https://www.smartverc.com/registration

(Continued from page 5)

Key Inputs from the earnings conference call held on 7 Feb 2020

...in January as well as towards in February, we see a remarkable difference in the sales on the positive side as far as the poultry industry is concerned.

Coming to the domestic sales versus exports, while the domestic sales have definitely been lower, the exports have shown reasonable amount of improvement, in fact on a quarter-to-quarter comparison, it has grown to around 2.5-3 times while on a 9-month comparison, it is showing a 66% growth.

...though the sales have been less in the last 3 quarters, we have kept up the pace and the budget in hiring sales people, marketing team... The spurt (in sales) has not come because of the various market reasons, but the hiring has taken place. The hiring continued in Q3 and once we are out of this situation, I am sure it would show a very steep growth in terms of sales. (number of employees has jumped almost three times from last year)

Looking at things further from here, the PPR and the Brucella are the two main vaccines for which we hope to get into a good business, not only in this quarter, but now in the next coming year or in the coming few years. (Government tender values could be about Rs 60 crores for Brucella and Rs 15 crores for PPR respectively for the current year. From next year onwards the opportunity in Brucella and PPR would be about Rs 700 crores and Rs 40 crores per year respectively)

Pending CAPEX at Tanzania would be around 25 to 30 crores. At present, there is no project expansion planning going on either in India or in Nepal.

- ✓ Due to small equity and high promoter stake big investors are unable to pick any stake.
- ✓ Moreover retail investors are often averse to buying high priced shares and thus stock becomes underpriced.
- ✓ On the top of it the company has recently declared to garner a sum of Rs 150 crores by diluting equity and this has dampened the share price. Equity will rise by about 12% only.

(Continued on page 8)

(Continued from page 7)

- ✓ During first six months of current year the profitability suffered due to steep rise in maize prices, farmers diverted their liquidity towards financing the higher cost of feed rather than spending on health products.
 - "...We welcome the announcement of the Government of India in ...Union Budget to work towards elimination of Foot-and-Mouth-Disease (FMD), Brucellosis disease & PPR disease by 2025, in cattle, sheep and goat in India.
 -Hester Biosciences manufactures Brucellosis & PPR vaccines. We have been and would continue contributing to this initiative of the Government through our vaccines which are available across the country."
 - Rajiv Gandhi, CEO & Managing Director
- ✓ Based on the first nine months performance we expect the company to deliver an EPS of about Rs 42 in the current year. Assuming achievable 35% growth in the next three years we are expecting an EPS of Rs 56 and Rs 76 and Rs 103.
- ✓ Stock was advised in -

Smart Gains

18 May 2016 @ 615

10 Oct 2018 @ 1057

04 Jun 2019 @ 1850

01 Jan 2020 @ 1441

Smart Multibaggers

10 Nov 2017 @1135 *

This report has been solely prepared with an intention to educate investors about the parameters / events / ratios to be considered before taking any action in any stock. This report should not be construed as a call to Buy / Sell or any kind of action. Kindly perform due research and study and even consultation with your advisor.

Frequently Asked Questions

Q. What is the Guarantee of success of the expected returns indicated in this report?

A. There is no Guarantee of meeting the expected returns, it is only a probability. Returns have been calculated based on our past experience and certain expectations from the company, industry and the economy.

Q. Can these stocks go down?

A. Recommendations are based on current valuations of these stocks with respect to the market. Any adverse news about the individual company or sharp correction in stock indices can drag the individual stock prices down.

Q. Will these stocks be reviewed in future?

A. At least One review shall be made as and when required.

Q. What is the minimum amount, one should invest in these stocks?

A. Limit your exposure in any single stock to maximum 5% of your total portfolio value.

Q. Stock advised by you is ruling up from your recommended price, can I still purchase this stock?

A. One can buy the stock as long as it is within the 5% band of recommended price.

Q. If I have a query, how and whom should I contact?

A. All the related queries shall be addressed to support@smartverc.com. We shall revert back to you within 24 hours.

Note:

Investors are advised not to borrow money even for the short term to invest in these stocks.

Subscription Details

Subscription rates as applicable at the time of subscription Add GST@18%

Smart Gains (Weekly @Wednesday)

Rs. 3200/- per year

Smart Multibagger Rs. 6500/- per year

Smart SIP (on 5th of every month)

Rs. 2500/- per year

Smart Freedom Portfolio Rs. 6000/- per year

Started with Rs 10 lacs present value Rs 16.78 Lacs on 12 Feb '20

Dr. Smart Restructure your portfolio and improve returns. Rs 3000/- per 25 stocks

Username & password will be provided to access the product from our website.

How to Subscribe

Online subscription from our website Visit: https://www.smartverc.com/subscribe

Disclosures / Disclaimer

Privacy Policy Your contact information will never be intentionally shared, rented or sold with any third party.

Disclosures

Recommendations given in this report have been researched and prepared by A K Asnani (SEBI Reg. - INH000000420). He has experience of 30 years into stock investments and author of book 'Way To Billionaire'. By qualification he is BE, MBA (Finance), ERA (ICFAI, Hyderabad) and pursuing PhD.

Smart VERC is a Bhopal based proprietorship firm with registration number: C / 544833. Address: 28, Sector 9-B, Saket Nagar, Bhopal - 462024.

Hence forth 'Team Smart VERC' implies the organisation including its owner, associates and employees.

It is declared that -

- No disciplinary action has been taken against team Smart VERC by any of the regulatory authorities.
- Team Smart VERC do not have any financial interest / beneficial interest of more than one percent / material conflict of interest in the companies covered in this advice letter
- Team Smart VERC has not received any compensation ever from the subject company(s) in any form.
- Team Smart VERC has not served at any post nor engaged in marketing of the company covered.

Disclaimer

The information in this document has been published on the basis of publicly available information on respective company websites, stock exchange websites, internal analysis and other reliable sources believed to be true but we do not represent that it is accurate or complete. Smart VERC has not independently verified all the information contained within this document.

Any projections and expected share prices are based on certain assumptions believed to be true and accurate, but are not verified in any way. Always do your own due diligence and use your own judgment when making any buying and selling decisions on your investments. Team Smart VERC shall not be responsible for any kind of loss / liability arising from the utilisation of the advice / views made in the report.

Concepts and strategies shared in this and any email communication from Smart VERC are ideas that have worked for members of our team, clients, and friends. Nothing in this document should be construed as investment or financial advice, or as an offer to sell or solicitation of an offer to buy any security. Always invest based on your specific risk return profile and financial position.

This document is not directed to, or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity, who is a citizen or resident or located in any locality, state, country or other jurisdiction, where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject Smart VERC to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, or Canada the same may be ignored.

All disputes subject to Bhopal jurisdiction only.